Results 211 to 220 of about 2,864,300 (339)
Experimental Study on the Urinary 17-KS Excretion in Acute Pancreatitis
Ichiro Inoue
openalex +2 more sources
The aim of this study was to determine if ERCP related morbidity is higher if performed out of workinghours. Contemporaneously collected data patients undergoing ERCP at an Australian hospital were analysed. No difference was found in rates of post‐ERCP pancreatitis (PEP) in patients undergoing out of hours ERCP compared with in hours ERCP (p = 0.759).
Hasib Ahmadzai+4 more
wiley +1 more source
Molecular and cellular mechanisms underlying gyrate atrophy: Why is the retina primarily affected?
Abstract Gyrate atrophy of the choroid and retina (GACR; OMIM #258870) is a rare early‐onset autosomal recessive disorder, caused by bi‐allelic pathogenic variants in the gene coding for ornithine aminotransferase (OAT) resulting in hyperornithinaemia.
Mark J. N. Buijs+12 more
wiley +1 more source
Acute Pancreatitis Caused by Fishbone Impaction in the Pancreas: A Case Report. [PDF]
Hang D, Ding K, Tang J, Ning B, Feng L.
europepmc +1 more source
Acute Pancreatitis Associated with an Intraluminal Duodenal Diverticulum
Francis C. Nance+2 more
openalex +1 more source
Acute Pancreatitis and Pancreatic Cancer Risk: A Nationwide Matched-Cohort Study in Denmark.
J. Kirkegård+3 more
semanticscholar +1 more source
Inherited thrombocytopenia (IT) caused by germline variants in RUNX1, ETV6 or ANKRD26 carries a high risk of developing haematological malignancy. This study examined the clinical, platelet and molecular characteristics of 66 patients with these conditions, who carried 24 distinct genetic variants in the corresponding genes.
Ana Marín‐Quílez+34 more
wiley +1 more source
Clinical Significance of Low-Density Granulocytes in Acute Pancreatitis. [PDF]
Wang J+11 more
europepmc +1 more source
Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen+3 more
wiley +1 more source